Handelsbanken Fonder
ALNY icon

Handelsbanken Fonder’s Alnylam Pharmaceuticals ALNY Stock Holding History

Handelsbanken Fonder’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.3M Sell
107,255
-29,207
-21% -$8.81M 0.09% 186
2026
Q1 		$45.2M Buy
136,462
+277
+0.2% +$94.3K 0.15% 118
2025
Q4 		$54.2M Sell
136,185
-19,184
-12% -$8.49M 0.16% 114
2025
Q3 		$70.8M Buy
155,369
+7
+0% +$2.85K 0.23% 86
2025
Q2 		$50.7M Buy
155,362
+38,679
+33% +$10.7M 0.18% 112
2025
Q1 		$31.5M Buy
116,683
+62,337
+115% +$16M 0.13% 155
2024
Q4 		$12.8M Sell
54,346
-18,835
-26% -$4.95M 0.05% 322
2024
Q3 		$20.1M Buy
73,181
+130
+0.2% +$33.8K 0.08% 230
2024
Q2 		$17.8M Sell
73,051
-2,055
-3% -$324K 0.08% 228
2024
Q1 		$11.2M Buy
75,106
+208
+0.3% +$34.7K 0.05% 332
2023
Q4 		$14.3M Sell
74,898
-94,845
-56% -$16.2M 0.07% 265
2023
Q3 		$30.1M Buy
169,743
+99
+0.1% +$18.9K 0.17% 138
2023
Q2 		$32.2M Sell
169,644
-1,645
-1% -$326K 0.17% 135
2023
Q1 		$34.3M Sell
171,289
-21,005
-11% -$4.42M 0.2% 120
2022
Q4 		$45.7M Buy
192,294
+64,701
+51% +$13.8M 0.29% 81
2022
Q3 		$25.5M Sell
127,593
-44,407
-26% -$8.47M 0.17% 149
2022
Q2 		$25.1M Buy
172,000
+600
+0.4% +$85.1K 0.16% 147
2022
Q1 		$28M Sell
171,400
-16,400
-9% -$2.5M 0.16% 148
2021
Q4 		$31.8M Buy
187,800
+167,700
+834% +$31.2M 0.16% 147
2021
Q3 		$3.79M Buy
20,100
+1,000
+5% +$188K 0.02% 515
2021
Q2 		$3.24M Sell
19,100
-1,200
-6% -$176K 0.02% 544
2021
Q1 		$2.87M Sell
20,300
-1,400
-6% -$211K 0.02% 539
2020
Q4 		$2.82M Buy
21,700
+2,500
+13% +$334K 0.02% 531
2020
Q3 		$2.8M Hold
19,200
– – 0.02% 486
2020
Q2 		$2.84M Buy
+19,200
New +$2.59M 0.02% 451
2016
Q1 		– Sell
-6,348
Closed -$598K – 249
2015
Q4 		$598K Buy
+6,348
New +$589K 0.01% 600

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Handelsbanken Fonder's ALNY Position: Q2 2026 in Review

Handelsbanken Fonder reduced its Alnylam Pharmaceuticals (ALNY) stake by 21% in Q2 2026, selling an estimated $8.81M and leaving 107,255 shares worth $32.3M. The position accounts for 0.09% of the portfolio, ranked #186.

Handelsbanken Fonder first reported a position in ALNY in Q4 2015 and has held it in 26 quarters since. The position peaked at $70.8M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Handelsbanken Fonder held 107,255 shares of Alnylam Pharmaceuticals worth $32.3M as of Q2 2026.
  • Handelsbanken Fonder sold 29,207 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $8.81M.
  • Alnylam Pharmaceuticals made up 0.09% of Handelsbanken Fonder's portfolio in Q2 2026, its #186 holding.
  • Handelsbanken Fonder first reported a position in Alnylam Pharmaceuticals in Q4 2015 and has held it in 26 quarters since.
  • Handelsbanken Fonder's Alnylam Pharmaceuticals position peaked at $70.8M in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.